

Supplementary Data

Figure S1. **A.** Raw counts for bouton area **B.** branch length **C.** active zone number per bouton **D.** Average bouton area and branch length for wild-type (w^{1118}) and $\text{foxo}^{\text{C431}}$. *P< 0.05, ** P<0.01, ***P>0.001, ****P< 0.0001, n.s. not significant. w^{1118} n=5; $\text{foxo}^{\text{C431}}$ n=5. **E.** Averaged bouton area and branch length. **F.** Raw bouton area and branch length for wild-type (w^{1118}) and $\text{foxo}^{\text{C431}}$. *P< 0.05, ** P<0.01, ***P>0.001, ****P< 0.0001, n.s. not significant. w^{1118} n=59; $\text{foxo}^{\text{C431}}$ n=66. **G.** **F.** Western analysis of FOXO protein abundance in control and Foxo^{21} mutant whole-body tissue.

Figure S2. **A.** Representative images of anti-Ac-Tub staining for wildtype (yw^R) at 1-week and 25-days of age, and foxo^{21} flies at 1 week of age. **B.** Representative images of anti-Ac-Tub staining for control (Ok6-Gal4> yw^R) at 1 week and 25 days of age, and Ok6-Gal4> foxo -RNAi flies at 1 week post eclosion. **C.** Quantification of acetylated alpha-tubulin structure. Significance values are compared to young control for each grouping . *P< 0.05, ** P<0.01, ***P>0.001.

Figure S3. **A.** Rab7 quantification at 1 week for ok6-Gal4> yw^R , ok6-Gal4>foxo-RNAi #1, ok6-Gal4> foxo-RNAi #2. **B.** Thor relative expression for whole body tissue. Daughterless-Gal4 activated with 200mM of RU486. **C.** Quantification of FOXO protein intensity in fat body nuclei after RU486 induced knockdown. * P< 0.05. **D.** Representative images of fat body tissue for control (S106-GS-GAL4> w^{1118}) and FOXO RNAi (S106-GS-Gal4>BL32993). S106-Gal4 activated with 200mM of Mifepristone (RU). Staining with anti-FOXO and DAPI. Scale Bar 10 μ m, n=5.

Figure S4. **A.** Rab7 relative intensity quantification at 1 week for ok6-Gal4> yw^R , ok6-Gal4>foxo-RNAi. **B.** Rab7 intensity quantification Rab7 quantification at 2-days for ok6-Gal4> yw^R , ok6-Gal4>foxo-RNAi **C.** Bouton area quantification at 2-days for ok6-Gal4> yw^R , ok6-Gal4>foxo-RNAi **D.** Ac-Alpha tubulin quantification at 2-days for ok6-Gal4> yw^R , ok6-Gal4>foxo-RNAi **E.** Quantification of Rab7 for epistasis flies. Values are set as a percentage with ok6-Gal4>Attp40 as baseline. *P< 0.05, n.s. – not significant.

Figure S5. Representative confocal images from genetic screening. **A.** anti-rab7 and anti-HRP immunofluorescence for ok6;foxo^{RNAi}> p38b^{RNAi}, ok6;foxo^{RNAi}> r1^{RNAi}, ok6;foxo^{RNAi}> p38a^{RNAi}. **B.** anti-rab7 and anti-HRP immunofluorescence for control (ok6-gal4> yw^R); ok6;foxo^{RNAi}> yw^R ; ok6;foxo^{RNAi}> babo^{RNAi}, **C.** anti-Ac-Tub and anti-HRP immunofluorescence for ok6;foxo^{RNAi}> p38b^{RNAi}, ok6;foxo^{RNAi}> babo^{RNAi}, ok6;foxo^{RNAi}> yw^R .

Figure S1






Figure S2

A



B



C

	Straight	Undulating
<i>ywR</i> 1wk	69.24%	30.76%
<i>yw^R</i> 25d	40.38%*	59.62%*
<i>yw^R</i> 40d	30.00%**	70.00%**
<i>foxo²¹</i> 1wk	46.83%*	53.17%*
ok6 > control 1wk	67%	33%
ok6 > <i>foxo-RNAi</i> 1wk	34.27%***	65.73%***
ok6 > control 25d	38.64%**	61.36%**

Figure S3




Figure S4






Figure S5

A



B



C

